A network update has introduced advanced AI-driven BioAgents, multichain support and other developments critical to the Bio Protocol ecosystem.
Bio Protocol’s native token has experienced a dramatic surge, rising 56% in the past 24 hours to reach $0.1238, with trading volume exceeding $164 million.
This rally comes after the token’s listing on South Korea’s premier cryptocurrency exchange, Upbit.
After a month-long decline, Bio Protocol (BIO) is showing signs of recovery.
Since October 1, the cryptocurrency had been in a steady downtrend, falling from $0.15 to a low of around $0.078.
The announcement of BIO’s listing on Upbit has acted as the immediate catalyst for the token’s explosive growth.
Upbit commands over 80% of South Korea’s crypto trading volume and has a storied history of propelling altcoins to new heights.
At the time of writing, BIO’s trading volume surged 820% in the last 24 hours to $311.55 million.
This listing builds on BIO’s exchange momentum, following debuts on Binance and Kraken.
BIO’s price is currently trading at $0.11, having shattered resistance at $0.09, and its market capitalization now stands at nearly $196 million according to CoinMarketCap’s data.
However, traders warn of potential pullbacks if broader market corrections materialize, emphasizing the need for sustained adoption beyond hype.
Adding to the momentum from the Upbit listing is the ongoing cheer of Bio Protocol’s recent news of a major network update.
The update and its momentum have further energized its community.
The update introduces enhancements to Bio Protocol’s staking mechanisms.
There’s also the integration of BioAgents, or AI-driven research assistants, with these aimed at automating hypothesis generation and experiment tracking.
“From AI co-scientists to biotech IP, over 8,000 participants joined the first wave of the new Bio Launchpad projects. These launches tokenized AI co-scientists and biotech IP, enabling communities to fund and own breakthroughs in stem-cell research, men’s health, and brain health. Each project bootstrapped onchain treasuries and liquidity, setting the foundation for incentive-aligned communities around real-world science.”
While aspects such as network slowdown affect immediate community outlook, Bio Protocol’s ability to bridge biotechnology innovation with decentralized governance is huge for BIO.
It redefines industry standards, offering investors a unique opportunity to participate in a transformative ecosystem.
Stakeholders are advised to monitor upcoming milestones, including the launch of new BioXP rewards and cross-chain developments.
The prevailing market conditions may count as potential hindrances to bullish advances.
